BioLargo Reports Q2 2025 Operating and Financial Results

Rhea-AI Summary

BioLargo (OTCQX:BLGO), a cleantech and environmental solutions company, reported its Q2 2025 financial results with revenues of $2.77 million for Q2 and $6.04 million for H1 2025. The company highlighted significant progress across multiple divisions, with its engineering segment experiencing a 517% revenue increase in air quality control services.

Notable achievements include Clyra Medical Technologies securing distribution agreements covering 6,100 hospitals and thousands of medical facilities, while the company's Cellinity battery technology received validation from U.S. BESS Corporation and secured four MOUs for potential factory partnerships. As of June 30, 2025, BioLargo maintained a strong financial position with $3.47 million in cash, total assets of $12.49 million, and stockholders' equity of $6.06 million.

Positive

• Engineering segment revenue increased by 517% from air quality control services
• Secured distribution agreements covering 6,100 hospitals, 6,300 surgery centers, and 2,200 wound care clinics
• Cellinity battery technology received validation from U.S. BESS Corporation
• Signed four MOUs for potential Cellinity battery factory partnerships
• Strong cash position of $3.47 million with $12.49 million in total assets

Negative

• Decreased revenue from Pooph pet odor product sales
• Market cap of $50 million potentially undervalues company assets according to management

Significantly Advances Energy Technologies and Clyra Medical Technologies

WESTMINSTER, CA / ACCESS Newswire / August 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Quarterly Report for the three and six months ended June 30, 2025. To view the filing in its entirety, please see:

https://www.biolargo.com/sec-filings.

BioLargo, Inc. President and CEO Dennis P. Calvert, commented, "Over the past few months and quarters, our team has done a tremendous job in progressing the value of the BioLargo portfolio. The unseen value is many multiples of our current $50 million market cap, driven by our unmatched technologies, capital-conserving strategy, highly qualified people and high impact. We are very optimistic with our emerging solutions surrounding surgical products, water treatment for the global PFAS contamination crisis and battery energy storage technology. Our team is focused on creating optimal partnerships to drive commercialization of these solutions across varying industries."

Key Highlights:

• Q2 2025 and 1st Half 2025 revenues of $2,777,000 and $6,046,000, respectively, primarily due to a decreased volume of sales of Pooph, our pet odor product private labeled to a third party.

• New engineering contracts to provide air quality control compliance services increased engineering segment revenue by 517%.

• Clyra Medical Technologies secured a series of sales and distribution agreements covering both U.S. and international markets, expected to make Clyra's products available by 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound care clinics in the U.S. alone.

• Independent evaluation conducted by U.S. BESS Corporation, an expert provider of advanced energy storage solutions for critical infrastructure applications, confirmed breakthrough performance of BioLargo's Cellinity battery technology for grid-scale energy storage.

• Cellinity, our revolutionary battery technology, signed four memoranda of understanding (MOUs) with perspective joint venture partners interested in building and operating Cellinity battery factories.

• Garratt Callahan, our co-development technology partners, continued support selling and business development targeting reuse of cooling tower water, for example at data centers.

• Engineering & Environmental Services is actively engaged with clients developing scope of work and budgeting for several significant projects.

• At June 30, 2025, stockholders' equity was $6.060,000, assets were $12,499,000, liabilities were $6,439,000, and the Company had $3,471,000 in cash and cash equivalents.

Learn more about BioLargo's environmental technologies at https://www.biolargo.com

About BioLargo, Inc.

BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at https://www.biolargo.com

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.

View the original press release on ACCESS Newswire

FAQ

What were BioLargo's (BLGO) Q2 2025 revenue results?

BioLargo reported Q2 2025 revenue of $2.77 million and H1 2025 revenue of $6.04 million, with a notable decrease in Pooph pet odor product sales.

How much did BioLargo's engineering segment revenue grow in Q2 2025?

BioLargo's engineering segment revenue increased by 517% due to new contracts in air quality control compliance services.

What is the market reach of Clyra Medical Technologies' distribution agreements?

Clyra secured agreements covering 6,100 hospitals, 6,300 ambulatory surgery centers, and 2,200 specialty wound care clinics in the U.S.

What is BioLargo's financial position as of June 30, 2025?

BioLargo had $3.47 million in cash, total assets of $12.49 million, liabilities of $6.43 million, and stockholders' equity of $6.06 million.

What progress has BioLargo made with its Cellinity battery technology?

Cellinity received validation from U.S. BESS Corporation for grid-scale energy storage and secured four memoranda of understanding with potential joint venture partners for battery factories.